Shares of Concord Medical Services Hldg Ltd (NYSE:CCM) have received a consensus broker rating score of 3.70 (Sell) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a sell recommendation.
Brokerages have set a 12-month consensus price target of $3.00 for the company, according to Zacks. Zacks has also assigned Concord Medical Services an industry rank of 94 out of 256 based on the ratings given to related companies.
NYSE CCM traded down $0.08 during trading hours on Thursday, reaching $2.45. The company’s stock had a trading volume of 3,000 shares, compared to its average volume of 7,762. The stock has a market cap of $101.47 million, a price-to-earnings ratio of -2.40 and a beta of 0.04. Concord Medical Services has a fifty-two week low of $2.30 and a fifty-two week high of $4.20.
About Concord Medical Services
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.
See Also: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with MarketBeat.com's FREE daily email newsletter.